EPIC-OSA

This is a Phase III, multicentre, randomised controlled trial aiming to evaluate whether a 12-month period of home positive airway pressure (PAP) therapy can decrease the frequency of moderate and severe respiratory exacerbations in individuals with COPD-OSA overlap syndrome, compared to standard COPD care alone.

Lead Research Facilitator: Jesu John Jacob

*Note on the EMIS Web Resources

The study team have intentionally left palliative care, nursing and care home patients included in the search to potentially be able to invite them where appropriate.

If you experience any problems downloading the information, please contact the primary care team: sc.rrdn@nihr.ac.uk

Disclaimer:

Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patient if required.

These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.

While we endeavour to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.